Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bolt Biotherapeutics, Inc.

0.3230
+0.02508.39%
Post-market: 0.32320.0002+0.06%19:30 EDT
Volume:972.97K
Turnover:283.40K
Market Cap:12.38M
PE:-0.20
High:0.3250
Open:0.2950
Low:0.2600
Close:0.2980
Loading ...

Bolt Biotherapeutics Inc trading halted, news pending

TIPRANKS
·
Yesterday

BRIEF-Bolt Biotherapeutics Announces 120 Reverse Stock Split Effective June 6, 2025

Reuters
·
Yesterday

Bolt Biotherapeutics Inc - Announces 1:20 Reverse Stock Split Effective June 6, 2025 - SEC Filing

THOMSON REUTERS
·
Yesterday

Bolt Biotherapeutics Announces 1-for-20 Reverse Stock Split Effective June 6, 2025

Reuters
·
05 Jun

Bolt Metals Corp. Announces Strategic Debt Settlement

TIPRANKS
·
04 Jun

Bolt Biotherapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
28 May

Bolt Biotherapeutics Initiated at Buy by Lake Street

Dow Jones
·
20 May

Cautious Hold on Bolt Biotherapeutics Amid Awaited Phase 1 Data and Strategic Decisions

TIPRANKS
·
17 May

Bolt Biotherapeutics Reports Q1 2025 Financial Results

TIPRANKS
·
13 May

Bolt Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Bolt Biotherapeutics Q1 EPS $(0.29) Beats $(0.36) Estimate, Sales $1.22M Beat $767.50K Estimate

Benzinga
·
13 May

Bolt Biotherapeutics Reports 77% Drop in Q1 Collaboration Revenue, Narrows Operational Loss to $12.1 Million

Reuters
·
13 May

Bolt Biotherapeutics, Inc. Q1 Net Income USD -11.04 Million

THOMSON REUTERS
·
13 May

Bolt Biotherapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
09 May

Sarah Nemec, Senior VP of Finance and PAO, Reports Acquisition of Common Shares in Bolt Biotherapeutics Inc

Reuters
·
06 May

William P. Quinn, President, CEO, and CFO, Reports Acquisition of Common Shares of Bolt Biotherapeutics Inc

Reuters
·
06 May

Bolt Biotherapeutics Presents Results From the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at Aacr Annual Meeting 2025

THOMSON REUTERS
·
26 Apr

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

GlobeNewswire
·
26 Apr

Cautious Hold Rating for Bolt Biotherapeutics Amidst Promising Developments and Uncertainties

TIPRANKS
·
12 Apr

Bolt Biotherapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar